Laird Thermal Systems Unveils Micro Multistage Thermoelectric Cooler & Optical TEAs Integration Capability

Laird Thermal Systems has developed the new OptoTEC™ MSX Series of micro multistage thermoelectric coolers and the capability to integrate them into various optical packages, including widely used TO-39, TO-46, or TO-8, creating advanced Optical Thermoelectric Assemblies (TEAs). The MSX Series utilizes advanced ceramic materials, proprietary solder bonding techniques and next-generation thermoelectric materials to boost cooling capacity by as much as 10% – all in a micro footprint. The Optical TEAs are designed for high-performance image sensing applications commonly used in analytical, industrial, and aerospace applications.

Thermal noise reduces image resolution as temperature increases. For high-end image sensing devices like IR detectors, X-ray detectors, CCD and CMOS sensors, deep cooling below ambient is required for the imaging sensor to capture maximum light spectrum.

The multistage MSX Series TECs offer micro footprints on the cold side down to 2.0 x 4.0 mm with thicknesses down to 3.3 mm for 2-stage, 3.8 mm for 3-stage and 4.9 mm for 4-stage coolers.

The packing fraction for thermoelectric elements enables a high heat pumping capacity up to 5 Watts, with lower operating currents than traditional multistage coolers. Featuring solid-state construction for long life reliability and no maintenance, the micro multistage thermoelectric coolers deliver reliable temperature stabilization from room temperature down to 180 Kelvin with no outgassing.

Manufactured in the USA, Laird Thermal Systems has invested in advanced automation equipment to integrate the multistage coolers into miniature optical packages in-house. This saves customers the burdensome task of integrating TECs into their packages, reducing assembly time and costs and improving repeatability.

“Advanced process automation has enabled a new level of miniaturization for our MSX multistage series to support next-generation imaging solutions that require smaller optical packages,” said Andrew Dereka, Thermoelectrics Product Director at Laird Thermal Systems. “Developing proprietary Optical TEA capabilities with minimal solder voiding ensures that our customers receive Optical TEAs with the highest quality, without the hassle of building assemblies themselves.”

The MSX Series is undergoing Telcordia GR-468 CORE qualification to ensure high repeatability and long-life operation in optical environments. More here.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”